Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference
Geneva, Switzerland, September 20, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will present at both the Sachs Associates 22nd Annual Biotech in Europe forum in Basel, Switzerland and the Baader Investment Conference in Munich, Germany taking place September 21 - 22, 2022 and September 23, 2022, respectively.
In his presentations, Mr. Dyer will provide a corporate update and discuss recent developments at Addex. A video of each presentation will be available for viewing on-demand by registered participants.
Mr. Dyer will also participate in a neurodegenerative diseases roundtable discussion with other panelists at the Sachs Associates Conference, scheduled on September 22, 2022.
Mr. Dyer will be available for one-on-one meetings throughout both conferences. For more information or to schedule a one-on-one meeting, please contact [email protected]
About Addex Therapeutics:
Forward Looking Statements: